沉默RGS7通过激活cGMP-PKG信号通路来减轻心房的进展
Hao Huang1, Yan Xiong2, Jie Zeng1
1Department of Cardiology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu City, PR China.
Biochimica et biophysica acta. Molecular basis of disease
|March 14, 2025
概括
沉默RGS7,心房动 (AF) 的关键基因,通过激活cGMP-PKG通路来减少AF的进展. 这一发现为管理这种常见的心脏病提供了新的治疗策略.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物标志物发现发现
背景情况:
- 心房动 (AF) 是一种普遍的心脏病,需要创新的管理策略.
- 确定可靠的生物标志物和调节途径对于有效的AF治疗至关重要.
研究的目的:
- 确定与心房动 (AF) 相关的潜在生物标志物和潜在的调节途径.
- 研究RGS7基因在AF病变发生中的作用及其治疗潜力.
主要方法:
- 使用基因表达综合数据库分析差异表达基因 (DEGs).
- 一个蛋白质-蛋白质相互作用 (PPI) 网络被构建来识别枢纽基因,包括RGS7.
- 进行了体内和体外实验,以评估RGS7操纵对AF指标和信号通路的影响.
主要成果:
- 包括RGS7在内的5个枢纽基因被确定,在区分AF与对照样本 (100%AUC) 中显示出高准确度.
- 静止RGS7在体外抑制了亡,炎症和氧化应激,同时改善了血管激素II治疗细胞中的线粒体功能.
- 在体内,RGS7沉默改善了AF老鼠的心脏功能和减少了纤维化,这与cGMP-PKG信号通路的激活有关.
结论:
- 沉默RGS7通过激活cGMP-PKG信号通路,有效地减轻心房动 (AF).
- RGS7 作为潜在的治疗标和AF管理的生物标志物.
相关概念视频
G-Protein Gated Ion Channels
4.5K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
4.5K
GPCRs Regulate Adenylyl Cylase Activity
5.1K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.1K
Amplifying Signals via Enzymatic Cascade
8.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K
GPCR Desensitization
5.7K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.7K
Activation and Inactivation of G Proteins
6.5K
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
6.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356


